The fund was located in Asia if to be more exact in Hong Kong. The main department of described Corporate Investor is located in the Hong Kong.
The standard case for the fund is to invest in rounds with 2 partakers. Despite the Medical Technologies Innovation Asia, startups are often financed by Platinum-Montaur Life Sciences. The meaningful sponsors for the fund in investment in the same round are Platinum Partners.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Echo Therapeutics. Besides, a startup requires to be at the age of more than 20 years to receive the investment from the fund. Among the most successful fund investment fields, there are Biotechnology, Therapeutics.
The fund is constantly included in less than 2 deals per year. Deals in the range of 10 - 50 millions dollars are the general things for fund. The high activity for fund was in 2013.
Fund Name | Location |
Annex Ventures | Dallas, Texas, United States |
Ayer Capital Management | California, San Francisco, United States |
Belt Road Capital Management | Cambodia, Phnom Penh |
C-III Capital Partners | - |
CVC2 | - |
Dentsu ScienceJam | Japan, Tokyo |
ICM Capital | England, London, United Kingdom |
Kraken | California, San Francisco, United States |
Levy Restaurants | Chicago, Illinois, United States |
MAIF Avenir | France, Ile-de-France, Paris |
Mohamad Moosa Abdulrahman Investment | - |
Nanjing Wuxiang Zichan | China, Jiangsu, Nanjing |
Phoenix Contact Innovation Ventures | Blomberg, Germany, Nordrhein-Westfalen |
Sofia Fund | Minneapolis, Minnesota, United States |
Synergia Capital Partners | Netherlands, Utrecht, Veenendaal |
Tech Wildcatters | Dallas, Texas, United States |
Zhejiang Silicon Paradise Asset Management Group | China, Hangzhou, Zhejiang |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.